“Our momentum is highlighted by the steady increase in physician adoption, positive patient feedback, and growing payer coverage, which form a strong foundation for long-term success. With a ...
The massive pharmacy benefit manager plans to stop requiring coverage reauthorizations for roughly 80 drugs used to treat ...
The PBM plans to stop requiring coverage reauthorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...
Optum Rx, the pharmacy benefit manager under UnitedHealth Group, is set to eliminate prior authorization requirements for ...
Optum Rx has eliminated reauthorization for almost 70 drugs for chronic diseases, about 10% of its overall pharmacy prior ...
Optum Rx is shifting its payment models to better meet the needs of pharmacies and consumers, the pharmacy benefit manager ...
Initiative will eliminate up to 25% of all reauthorizations, or 10% of overall prior authorizations, PBM says.
The PBM is pivoting to a cost-based reimbursement model, which it says will reduce variation in how pharmacies are paid.
Cash Position & Operating Runway: As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback